← All stocks

X4 Pharmaceuticals, Inc

XFOR Net selling
CIK 0001501697 #3276 in the set updated 18 Sep 2026
Bought (12 mo)
$250.00K
out of their own pocket, the only kind of buying there is
Sold (12 mo)
$429.31K
$0.00 on a plan · $0.00 straight out of an exercise
Sold at will
$429.31K
4 of 4 sales
Net
−$179.31K
−$179.31K against sales at will

By person

16 insiders · 5 transactions
Insider
Role
Bought
Sold
Net
Holding
Worth
Change
KIRSKE DAVID
Chief Financial Officer
$109.25K (2)
−$109.25K
167,750
$745.56K
Volpone John
President
$109.23K (1)
−$109.23K
265,305
$1.18M
Craig Adam R
Executive Chairman
$250.00K (1)
$210.83K (1)
+$39.17K
328,651
$1.46M
Ragan Paula
President and CEO
3,337,386
$14.83M
+336.2%
DiBiase Mary
Chief Operating Officer
1,140,980
$5.07M
+294.7%
Arbet-Engels Christophe
Chief Medical Officer
864,207
$3.84M
Mostafa Adam S.
Chief Financial Officer
850,000
$3.78M
Taveras Arthur
Chief Scientific Officer
388,026
$1.72M
+65.6%
Baldry Mark
Chief Commercial Officer
25,337
$112.61K
Thoren Natasha Fay
Chief Legal Officer
9,462
$42.05K
+54.4%
Stewart Murray
Director
7,883
$35.04K
+23.5%
Woods Keith
Director
6,000
$26.67K
+33.3%
WYZGA MICHAEL S
Director
5,555
$24.69K
+37.0%
MCGIRR DAVID W J
Director
4,722
$20.99K
+46.6%
Bridger Gary
Director
4,722
$20.99K
+46.6%
de Craecker Francoise
Director
4,722
$20.99K
+46.6%

No percentages here. This company's share count has moved by a factor of 15.2 over the window, from 11,408,357 to 173,662,376 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.

Nothing of that kind in this period.

What was left out

Form 4 filings counted 13
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 0
Sales at will 4
Transactions with no price 0
Shares from compensation/vesting 0
History held since 20 Nov 2017